Platinum chemotherapy during pregnancy for serous cystadenocarcinoma of the ovary.
Ovarian carcinoma in pregnancy remains a rare event. Although concern regarding the gestation complicates therapy, platinum drug-based combination chemotherapy is often deemed warranted in such cases. We report the antepartum use of cisplatin, followed by carboplatin, for an ovarian serous cystadenocarcinoma. During this treatment, serial sonographic assessment of fetal morphometric parameters and biophysical profiles with fetal heart rate monitoring were performed to document fetal well being. Platinum-DNA adducts were measured in maternal blood, placenta, fetal amniotic cells, and cord blood. This report represents an attempt to define platinum drug transfer in utero and fetal growth and development during therapy and to document the first use of carboplatin in pregnancy.
Henderson
C E
CE
Department of Obstetrics and Gynecology, Jack D. Weiler Hospital, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York.
Elia
G
G
Garfinkel
D
D
Poirier
M C
MC
Shamkhani
H
H
Runowicz
C D
CD
D000328:Adult; D016190:Carboplatin / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use*; D003536:Cystadenocarcinoma / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D011256:Pregnancy Outcome; D016896:Treatment Outcome
D016190:Carboplatin; D002945:Cisplatin